MISSISSAUGA, Ontario – (COMMERCIAL THREAD) – MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that the Company has agreed to settle an amount of $ 65,000 due to professional advisor, subject to all relevant consents and approvals, by issuing 500,000 common shares to the seller , priced at $ 0.13 per share. Regulatory and other consents will include acceptance of the TSX Venture Exchange.
MedX, headquartered in Mississauga, Ontario, is a leading skin health-focused medical device and software company with its SIAscopy telemedicine platform on DermSecure ™, using its SIAscopy ™ technology. SIAscopy is also integrated with its SIAMETRICS ™, SIMSYS ™ and MoleMate ™ products, which MedX manufactures in its ISO 13485 certified factory. SIAMETRICS ™, SIMSYS ™ and MoleMate ™ include portable devices that use patented technology using light and its transfer to visualize up to 2mm under moles and suspicious lesions in a painless and non-invasive way, with its software then creating real -time images allowing doctors and dermatologists to assess all types of moles. beauty or lesions in seconds. These products are approved by Health Canada, FDA, TGA, and CE for use in Canada, United States, Australia, New Zealand, European Union, Turkey, and Brazil. MedX also designs, manufactures and distributes quality therapeutic and dental photobiomodulation lasers to provide drug-free and non-invasive treatment for tissue damage and pain. www.medxhealth.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This press release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. Forward-looking statements involve risks and uncertainties.